In 2002, the Women’s Health Initiative published the results of a large randomized controlled trial of hormone replacement therapy, and the results appeared to be alarming: women taking combined estrogen-progestin therapy had higher rates of breast cancer, cardiovascular disease, and stroke than those taking placebo. The press coverage was immediate and sweeping. HRT prescriptions in the United States dropped by more than 50% within months. An entire generation of women approaching menopause concluded that hormone therapy was dangerous and were not offered alternatives.

The problem is that the WHI findings were considerably more complicated than the initial interpretation — and what medicine has been slowly and somewhat reluctantly working through in the 20 years since is that the nuanced reading of the data supports different conclusions.

What Actually Happens

Menopause is defined as the cessation of menstruation for 12 consecutive months, typically occurring between 45 and 55 years of age, with an average of 51 in Western countries. But the clinical definition covers a process that begins years earlier: perimenopause, the transition period that can last 4 to 10 years, characterized by irregular periods, hormonal fluctuation, and the onset of menopausal symptoms.

The physiological reality of menopause is a permanent decline in estrogen and progesterone production as the ovaries reduce their activity. The consequences are wide-ranging and not fully captured by the standard list of symptoms. Yes, hot flashes — technically “vasomotor symptoms” — affect 75-80% of women in perimenopause and menopause, with around 25% experiencing them as severe. Yes, sleep disruption is common and compounding. Yes, vaginal and urinary changes (genitourinary syndrome of menopause, GSM) affect around 40-60% of women in menopause and are progressive without treatment.

But the effects extend beyond these obvious symptoms. Estrogen plays a role in maintaining bone density, cardiovascular protection, lipid metabolism, cognitive function, skin integrity, and collagen production. The post-menopausal decline in estrogen is associated with increased cardiovascular risk (menopause is a significant inflection point in women’s heart disease risk), accelerated bone loss and osteoporosis risk, and — in ways that are still being researched — changes in cognitive function and possibly increased Alzheimer’s risk.

The WHI Revisited

The WHI study, whose findings seemed so alarming in 2002, used a specific population and a specific formulation of hormone therapy. The average age of participants was 63 — well past the menopausal transition. They were given oral conjugated equine estrogen combined with medroxyprogesterone acetate, a synthetic progestin. The increased breast cancer risk found in the study was modest (less than one additional case per 1,000 women per year) and associated specifically with the combined therapy; women who had had hysterectomies and took estrogen alone showed no increased risk.

What the 2002 interpretation missed was the “timing hypothesis”: the benefit-risk profile of hormone therapy is significantly different depending on when it is started relative to menopause. Women who begin hormone therapy within 10 years of menopause — or before age 60 — show a different pattern of outcomes than women who begin in their 60s. In the former group, there is evidence of cardiovascular protection, bone preservation, and cognitive benefit. In the latter group, introducing hormones into a system that has been without them for a decade may have different and less favorable effects.

The reanalysis of the WHI data, published by researchers including JoAnn Manson and Rowan Chlebowski over the following decade, along with substantial additional research, has substantially changed the clinical picture. In 2022, the Menopause Society (formerly NAMS) updated its guidelines to reflect the evidence that hormone therapy is appropriate and safe for most women under 60 within 10 years of menopause, and that the blanket risk warnings of the post-WHI era were not supported by careful reading of the data.

Women who were denied hormone therapy in the years following 2002 — who suffered through severe symptoms while their physicians withheld treatment based on an overreading of a complicated study — are a generation with a legitimate grievance.

What Gets Better

The narrative of menopause in Western culture is almost entirely one of loss: loss of fertility, loss of youth, loss of attractiveness, loss of hormonal stability. This narrative is both inaccurate and harmful, not least because the experience it anticipates shapes the experience women have.

Research on wellbeing across the menopausal transition tells a more varied story. A 2016 longitudinal study by Nancy Woods and Ellen Mitchell found that while menopausal symptoms (particularly in perimenopause) are associated with decreased quality of life, postmenopause is associated for many women with improved wellbeing relative to the perimenopausal period. The years immediately post-menopause, when symptoms have stabilized or been treated, are reported by many women as a time of greater freedom, clarity, and even energy than the years of perimenopause.

There is also substantive evidence that what is called “post-menopausal zest” is real — anthropologist Margaret Mead coined the phrase, and it has been confirmed in qualitative research. The freedom from premenstrual syndrome, from menstrual pain, from the anxiety of pregnancy risk, from the hormonal volatility of perimenopause — these are real improvements in daily life that the culturally dominant narrative of loss ignores.

Many women report, in midlife, a growing clarity about what matters, a decreasing concern with social approval, and an increased capacity to set boundaries. Research on self-esteem and assertiveness across the lifespan finds that these tend to increase, not decrease, from the 40s onward. Some research on creative productivity finds similar patterns: women’s creative output often reaches a peak in the years following menopause.

How Other Cultures Frame Menopause

The cross-cultural picture on menopause is striking, and it challenges the assumption that the Western medical model — menopause as disease requiring treatment — is the neutral baseline.

The sociologist Margaret Lock’s foundational comparative research, published in her 1993 book Encounters with Aging, compared menopausal experience among Japanese, Canadian, and American women. Her finding was that Japanese women reported significantly lower rates of hot flashes and the most distressing menopausal symptoms — not because Japanese women’s biology is fundamentally different, but because the experience of menopause is shaped by cultural framing, diet (soy-rich diets provide phytoestrogens), and the different social status of postmenopausal women in Japanese culture.

In many Indigenous cultures, including several Native American traditions, postmenopausal women hold recognized positions of wisdom and authority. The postmenopausal woman is an elder, a healer, a keeper of knowledge. Her status increases, not decreases. The specific symptoms associated with menopause in Western women may be partly a function of the status anxiety that accompanies what Western culture treats as a social descent.

In South Asian cultures, research by researchers including Uma Devi Mehrotra has found that middle-class Indian women who anticipate the postmenopausal period as a transition to greater social freedom — relief from menstrual taboos, freedom from the specific demands of reproductive-age womanhood — experience the transition more positively than those who frame it through a Western lens of loss.

None of this means symptoms are “just cultural” or that women who experience severe symptoms are simply the victims of their cultural framing. The vasomotor symptoms of menopause are physiological, measurable, and for many women severe enough to require treatment. But the meaning attributed to the transition, the social status of the postmenopausal woman, and the cultural narrative of what life after menopause looks like — these genuinely affect how the transition is experienced.

The Treatment Landscape in 2026

The treatment options available for menopausal symptoms are considerably more varied in 2026 than they were in 2002. Hormone therapy remains the most effective treatment for vasomotor symptoms, and the evidence base for its safety when initiated at the appropriate time has strengthened considerably. Body-identical (bioidentical) hormones — particularly transdermal estradiol and micronized progesterone — have a somewhat different risk profile than the synthetic hormones used in the WHI trial and are now first-line in updated guidelines.

Non-hormonal options have also expanded. Fezolinetant, an NK3 receptor antagonist, was approved in 2023 as the first non-hormonal medication specifically targeting hot flashes. SSRIs and SNRIs are used for vasomotor symptoms in women for whom hormone therapy is contraindicated. Cognitive behavioral therapy has evidence for reducing the distress associated with hot flashes, if not their frequency.

The genitourinary syndrome of menopause — the vaginal dryness, urinary frequency, and discomfort that affects many postmenopausal women and was historically barely discussed — is treatable with local estrogen preparations (vaginal rings, creams, tablets) that have essentially no systemic absorption and very limited risks, even in women who should not take systemic hormones.

What has not kept pace with the clinical evidence is how readily the treatment landscape is communicated to women. Research consistently finds that many women approaching and experiencing menopause have not been informed about treatment options, have been offered them only if they raise symptoms explicitly, and have absorbed the post-2002 message that hormone therapy is dangerous in ways that have not been corrected by their healthcare providers.

The conversation that medicine is finally having needs to reach the women who need it.

Related reading on Vanity-X: